Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA to prepare label extension in the US for the treatment of post-surgical neuropathic pain finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Grünenthal Germany is a Great Place to Work®
News provided by
Share this article
Great Place to Work
® and a
Great Start! company for apprentices. The company was awarded these two certifications based on the positive feedback that its employees shared during the
Great Place to Work
® survey in 2020 and a successfully completed external audit. We are pleased with this positive feedback from our employees particularly in times of the pandemic. It shows us that employees feel connected to the company – despite contact restrictions and working from home, says Oliver Lamm, Head HR Germany. At Grünenthal we actively create an attractive working environment based on our strong corporate culture.
Grünenthal Germany is a Great Place to Work® prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
Aachen, Germany, 12 February
2021 / News Aktuell – Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader context of the company’s acquisition of the European rights (excluding Spain and the UK) to the lipid-lowering medication CRESTOR™ completed in February 2021. The term loan maturities are now aligned with Grünenthal’s Revolving Credit Facility maturity, which further extends its debt maturity profile. More than 60 percent of Grünenthal’s debt facilities now mature in 2024 or later.
“By extending the maturity of our financing, we have gained additional flexibility to further fund our growth strategy,” says Fabian Raschke, Chief Financial Officer of Grünenthal. „W
Grünenthal closes deal with AstraZeneca for European rights to CRESTOR (rosuvastatin)
AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR (excluding Spain and the UK) for a total consideration of up to US$ 350 million. Cardiovascular diseases are among the most burdensome diseases in Europe
1, said Gabriel Baertschi, CEO Grünenthal. With CRESTOR, we are proud to provide a meaningful therapy option to those patients. The completion of this acquisition is an important milestone for Grünenthal.
Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR and its second brands in more than 30 European markets. Grünenthal will also take over bulk production and packaging for the defined markets by 2025. CRESTOR continues to generate significant revenues, total CRESTOR 2019 sales in the countries where rights were acquired were US$ 136 milli